Lil­ly and In­novent look to bring their an­ti-PD-1 from Chi­na to the US; Mer­ck KGaA names new EMD Serono pres­i­dent

Af­ter win­ning two reg­u­la­to­ry ap­provals in Chi­na for a PD-1 in­hibitor, Eli Lil­ly and In­novent are look­ing to bring the drug to the US.

The pair sub­mit­ted their BLA for sin­til­imab, brand­ed as Tyvyt in Chi­na, in com­bi­na­tion with peme­trexed and plat­inum chemo on Tues­day for the first-line treat­ment on non­squa­mous NSCLC. The ap­pli­ca­tion comes on the heels of a Phase III tri­al where pa­tients in the drug arm saw a me­di­an pro­gres­sion-free sur­vival of 8.9 months, as op­posed to just five months among those tak­ing the place­bo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER